Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants With Hereditary Angioedema (The ALPHA-STAR Trial)

NCT05695248 is registered in ClinicalTrials.gov with Astria Therapeutics, Inc. as lead sponsor.

NCT NCT05695248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05695248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants With Hereditary Angioedema (The ALPHA-STAR Trial)
Lead sponsor
Astria Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 21, 2023
Completion date
March 13, 2025
Enrollment
29 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema